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Abstract 
The UGT1A1*28 polymorphism was suggested to be significantly connected with 
irinotecan-induced toxicity and response to chemotherapy. However, the results of previous 
studies are controversial. Hence we carried out a meta-analysis to investigate the effect of 
UGT1A1*28 polymorphism on severe diarrhea, neutropenia, and response of patients who had 
undergone irinotecan-based chemotherapy. The PubMed, Web of Science, Wanfang, and CNKI 
databases were searched for clinical trials assessing the association of UGT1A1*28 polymorphism 
with severe diarrhea, neutropenia, and response to irinotecan-based chemotherapy. The 
combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the 
relationship under a fixed- or random-effects model. Fifty-eight studies including 6087 patients 
with cancer were included. Our results showed that patients carrying the TA6/7 and TA7/7 
genotypes had a greater prevalence of diarrhea and neutropenia than those with the TA6/6 
genotype (TA6/7+TA7/7 vs. TA6/6: diarrhea, OR = 2.18, 95%CI = 1.68-2.83; neutropenia, OR = 
2.15, 95%CI = 1.71-2.70), particularly patients with metastatic colorectal cancer. Stratified analysis 
showed that Asians with the TA6/7 and TA7/7 genotypes were more likely to have diarrhea and 
neutropenia, and Caucasians with the TA6/7 and TA7/7 genotypes were more likely to have 
neutropenia than other groups. However, patients with the TA6/7+TA7/7 genotypes showed a 
higher response than patients with TA6/6 genotype (OR = 1.20, 95%CI = 1.07–1.34), particularly 
Caucasians (OR = 1.23, 95%CI = 1.06–1.42) and patients with metastatic colorectal cancer (OR = 
1.24, 95%CI = 1.05–1.48). Our data showed that the UGT1A1*28 polymorphism had a significant 
relationship with toxicity and response to irinotecan-based chemotherapy. This polymorphism 
may be useful as a monitoring index for cancer patients receiving irinotecan-based chemotherapy. 
Key words: UGT1A1*28, diarrhea, neutropenia, response. 
Introduction 
According to the estimation, there are probably 
1,658,370 people suffer from cancer and 589,430 
people die of cancer in the United States in 2015[1]. In 
China, the corresponding data were 4,292,000 and 
2,814,000 in 2015, respectively, which means cancer is 
an urgent problem to be solved [2]. Several methods 
such as surgery, radiotherapy, and chemotherapy are 
widely applied for the clinical treatment of cancer. 
Irinotecan-based chemotherapy is one of the most 
used chemotherapies for patients with advanced 
gastric cancer, ovarian cancer, metastatic colorectal 
cancer, and other cancers [3-5]. Irinotecan, a 
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camptothecin derivative, is mainly transported into 
liver by solute carriers and metabolized into 
ametabolite, SN-38, by a carboxylesterase [6]. In turn, 
SN-38 is glucuronidated by uridinediphosphate 
(UDP)-glucuronosyltransferases (UGTs) to an inactive 
form, SN-38G. Lower glucuronidation rates lead to 
higher SN-38 concentrations, resulting in 
irinotecan-induced severe toxicity [7]. Diarrhea and 
neutropenia are the most common side effects of 
irinotecan-based chemotherapy, limiting its 
application [8]. Recent studies have confirmed 
thatUDP UGT 1A1 play a vital role in the process of 
glucuronidation [9, 10]. 
The UGT1A1*28 polymorphism contains an 
extra TA repeat in the 5′-promoter region, whose 
mutant genotype is A(TA)7TAA (TA7/7) and has a 
wide genotype of A(TA)6TAA (TA6/6). Toffoli et 
al.[11] found that UGT1A1*28 TA7/TA7 genotype is 
related to a lower glucuronidation ratio. Previous 
studies investigated the relationship of UGT1A1*28 
with neutropenia and diarrhea and have shown 
conflicting results. TA6/6 was reported to be a main 
predictive factor for diarrhea in a study of 56 
advanced colorectal carcinoma (CRC) [12]. In contrast, 
some studies found that patients with the TA6/7 or 
TA7/7 genotypes are more inclined to suffer severe 
neutropenia and diarrhea [13-16]. However, no 
correlation was defined between the UGT1A1*28 
polymorphism and neutropenia according to data 
from Hirata et al.[17] and Ferraldeschi et al.[18]. 
To clarify the predictive value of the UGT1A1*28 
polymorphism in patients receiving irinotecan-based 
chemotherapy, we conducted this study to investigate 
the impact of the UGT1A1*28 polymorphism on 
tumor response and the common toxicities, diarrhea 
and neutropenia. 
Materials and methods 
Publication Search 
Studies were selected by retrieving the Web of 
Science, PubMed, CNKI, and WanFang databases, up 
to June 2016. Similar keywords were used in different 
databases: “UGT1A1*28” and “diarrhea,” 
“UGT1A1*28” and “neutropenia,” “UGT1A1*28” and 
“response,” “UGT1A1*28” and “irinotecan,” 
“UGT1A1*28” and “CPT-11,” and related terms. No 
language restrictions were applied. All qualified 
studies were searched and a cross search was also 
used to identify the remaining relevant studies. When 
overlapping data exist in different reports, the most 
complete article was included. Disagreements 
between two authors will be settled by discussion and 
consensus. 
Selection Criteria 
Studies were included if they fulfilled the 
following criteria: (a) clinical trials; (b) evaluated the 
association of the UGT1A1*28 polymorphism with 
irinotecan-induced toxicities and chemotherapeutic 
effect; and (c) contained key information about the 
number of patients who have severe diarrhea, 
neutropenia and response to chemotherapy or not. 
Duplicate studies, review articles, letters, non-original 
studies, or case reports were excluded.  
Data Extraction 
Detailed information of included studies had 
been extracted and recorded in a standardized table 
by two reviewers. The following information was 
recorded: first author’s surname, year of publication, 
ethnicity, cancer subtype, methods of mutation 
detection, number of patients with and without 
response, severe diarrhea and neutropenia, genotypes 
were extracted. If these data were not reported, items 
were marked “NR” (not reported). 
Data Synthesis 
This meta-analysis was conducted according to 
the PRISMA guidelines [19]. We used the 
Newcastle-Ottawa-Scale (NOS) to assess the qualities 
of including studies and calculated the combined odd 
ratios (ORs) and 95% confidence intervals (CIs) to 
evaluate the strength of relationship between the 
UGT1A1*28 polymorphism and irinotecan-induced 
diarrhea or neutropenia under the four models 
(TA6/7 vs. TA6/6, TA7/7 vs. TA6/6, TA6/7+TA7/7 
vs. TA6/6, and TA7/7 vs. TA6/6+TA6/7) [20]. The 
association between tumor response and the 
UGT1A1*28 polymorphism was calculated only in the 
dominant model (TA6/7+TA7/7 vs. TA6/6). Pooled 
ORs were tested by the Z test, and a P value <0.05 was 
considered significant. Chi-square test and Q test 
were used to examine the heterogeneity among the 
studies. We also performed stratified analysis 
depending on tumor types (advanced gastric cancer, 
metastatic non-small cell lung cancer, metastatic 
colorectal cancer, or others), ethnicity (Asian, 
Caucasian or mixed people) and study design 
(retrospective or prospective study). Publication bias 
were determined by Egger’s and Begg’s tests [21, 22]. 
Specific methods are described in our pervious study 
[23]. A trim and fill method of adjusting for 
publication bias was carried out when the P value of 
Egger’s test was less than 0.05 [24]. Trial sequential 
analysis (TSA) was conducted to calculate the 
required sample size to get a robust conclusion [20]. 
When P values of two-sided comparisons were less 
than 0.05, we considered the difference was 
significant. We performed all the statistical 
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calculations by STATA 12.0 (StataCorp LP, College 
Station, TX, USA). 
Results 
Characteristics of the Studies Included 
As shown in Figure 1, we performed the primary 
literature retrieval using the PubMed, Web of Science, 
Wanfang, and CNKI databases by the end of June 
2016. First, 307 articles were included and 119 articles 
were excluded after searching for duplicates. Second, 
we read the titles and abstracts and excluded 78 
articles because they were letters, case reports, 
reviews or reporting about other polymorphisms. 
Finally, after reading the full-text of all articles, 53 
articles were excluded due to lacking of useful data or 
evaluation about other toxicities and 58 studies from 
57 articles including 6087 patients with cancer were 
found to meet the inclusion criteria.  
 
 
 
Figure 1. Flow diagram of included studies for the meta-analysis. CNKI = China 
National Knowledge Infrastructure 
 
Among these studies, 16 studies investigated the 
associations in Caucasians [11-15, 18, 25-35], 40 in 
Asians [3, 9, 16, 17, 36-62], and two in mixed 
population or not reported [63, 64]. All studies were 
retrospective or prospective studies, including 29 
metastatic colorectal cancer (mCRC) studies, five 
metastatic non-small cell lung cancer (mNSCLC), 
three advanced gastric cancer (GC) studies, two SCLC 
studies, and two advanced esophageal cancer studies 
and others. Table 1 summarized the basic information 
of the included studies. 
Meta-Analysis of UGT1A1*28 Polymorphism 
and Severe Diarrhea 
There were 44 studies of 4868 patients to 
evaluate the relationships between the UGT1A1*28 
polymorphism and irinotecan-induced severe 
diarrhea. As shown in Table 2 and Figure 2, we found 
the UGT1A1*28 polymorphism was significantly 
related to severe diarrhea risk under all comparisons 
(TA 6/7 vs. TA6/6: OR = 1.56, 95%CI = 1.25-1.96; 
TA7/7 vs. TA6/6: OR = 3.97, 95%CI = 1.88-8.38; TA 
7/7 vs. TA6/7+TA6/6: OR = 3.64, 95%CI = 2.01-6.58), 
regardless of the study design. By performing the 
subgroup analysis, we confirmed the relationship in 
the Asian group (TA6/7 vs. TA6/6: OR = 1.85, 95%CI 
= 1.37–2.50, P<0.001; TA7/7 vs. TA6/6: OR = 8.98, 
95% CI = 5.21–15.47, P<0.001; TA6/7+TA7/7 vs. 
TA6/6: OR = 2.74, 95%CI = 2.21–3.40, P<0.001; TA 7/7 
vs. TA6/6+TA6/7: OR = 8.64, 95%CI = 4.14–18.04, 
P<0.001) and in Caucasians (TA7/7 vs. 
TA6/6+TA6/7: OR = 1.62, 95%CI = 1.03–2.53). 
Stratified analysis according to cancer type was also 
carried out in this study. Individuals with mCRC 
carrying the TA7/7 or TA6/7 genotypes had a higher 
risk of getting diarrhea after irinotecan-based 
chemotherapy compared with the TA6/6 genotype 
(TA6/7 vs. TA6/6: OR = 1.60, 95%CI = 1.11–2.31, P = 
0.011; TA7/7 vs. TA6/6: OR = 3.53, 95%CI = 1.54–8.09, 
P = 0.003). The same risk was also seen in SCLC 
patients (TA6/7+TA7/7 vs. TA6/6: OR = 3.95, 95%CI 
= 1.42–11.01, P = 0.009; TA7/7 vs. TA6/6+TA6/7: OR 
= 19.90, 95%CI = 2.57–154.1, P = 0.004).  
Meta-Analysis of UGT1A1*28 Polymorphism 
and Severe Neutropenia 
The relationships of the UGT1A1*28 
polymorphism with irinotecan-induced severe 
neutropenia risk were investigated in 49 studies of 
5232 patients. The UGT1A1*28 polymorphism was 
significantly related to an increased severe 
neutropenia incidence (Table 3 and Figure 3, TA 6/7 
vs. TA6/6: OR = 1.71, 95%CI = 1.41-2.08; TA7/7 vs. 
TA6/6: OR = 5.34, 95%CI = 3.05-9.33; TA 7/7 vs. 
TA6/7+TA6/6: OR = 4.12, 95%CI = 2.36-7.20). 
Caucasians and Asians with at least one TA7 allele 
had a higher risk of neutropenia (Caucasians: TA6/7 
or TA7/7 vs. TA6/6: OR = 1.84 and 5.67; Asians: 
TA6/7 or TA7/7 vs. TA6/6: OR = 1.56 and 4.77). In 
the analysis stratified by cancer type and study 
design, an association was also found in retrospective 
and prospective designs, with mCRC patients having 
the TA7/7 and TA6/7 genotypes (TA6/7 or TA7/7 
vs. TA6/6: OR = 1.76 and 5.07) and solid tumor 
patients with the TA7/7 genotype (TA7/7 vs. TA6/6 
or TA6/6+6/7: OR = 7.66 and 6.68). 
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Table 1. Characteristics of the Studies Included in the Meta-Analysis 
Study Year Study 
design 
Race Cancer Mutation 
detection 
methods 
Regimen IRI dose (mg/m2)/schedule Popula-
tion 
source 
No. of 
patients 
Age ECOG NOS 
Yan8 2016 R Asian mixed tumors PCR-Sanger 
sequence 
FOLFIRI, IRI + CDDP, 
IRI + BEV 
125, 150 or 180 mg/m2 S 157 53 NR 8 
Xu64 2016 R Asian mCRC Direct 
Sequencing 
FOLFIRI, IRI+CAP 150mg/m2, every 2 or 3 weeks S 183 NR 0-1 9 
Gui65 2016 R Asian mCRC SPR FOLFIRI, IFL 180mg/m2, every 2 or 3 weeks S 384 NR 0-2 8 
Wang5 2016 P Asian Advanced GC SPR IRI+CDDP 80 or 125mg/m2 S 40 54 0-2 8 
Li4 2016 P Asian mCRC SPR FOLFIRI, mCapeIRI, 
IRI 
NR M 160 50 0-2 9 
Yang63 2015 R Asian pancreatic or 
biliary tract 
cancer 
Direct 
Sequencing 
FOLFIRI, IRI alone 180mg/m2, biweekly  S 48 56.2 0-1 7 
Peng60 2015 P Asian mCRC Sequencing FOLFIRI; mFOLFIRI 180mg/m2, biweekly S 208 59.8 0-3 7 
Wu59 2015 P Asian Advanced 
esophageal 
cancer 
NR IRI+PLA 180mg/m2, every 3weeks S 42 55 0-2 7 
Xu3 2015 NR Asian advanced OC PYRS IRI+CDDP 60mg/m2 IRI (d1, 8) every 3 weeks S 89 48 NR 7 
Xiao9 2015 R Asian SCLC PYRS IRI+CDDP/CBP/LOB 60 mg/m2 (d1,8,15), every 4 weeks; 
85mg/m2 (d1,8), every 3 weeks 
S 67 NR 0-2 8 
Shi61 2015 P Asian SCLC Direct 
Sequencing 
IRI+CDDP 65mg/m2 (d1, 8) M 30 59 0-2 8 
Atasilp10 2015 R Asian mCRC PYRS FOLFIRI, 
FOLFIRI+CET, 
FOLFIRI+BEV, 
mFOLFIRI, IRI alone, 
IRI+CET/CAP 
180mg/m2, biweekly; 100mg/m2 S 44 6 0-2 7 
Chen62 2015 P Asian mNSCLC Sequencing IRI+DDP 100mg/m2, every 3 weeks S 86 63 0-2 8 
Wang35 2015 P Asian mCRC Sequencing NR NR S 111 NR 0-1 7 
Li54 2014 R Asian mCRC PYRS FOLFIRI, IRI + 
CET/BEV, IRI + RAL, 
IRI+ CAP 
180 mg/m2, every 2 or 3 weeks S 167 50 0-2 8 
Hirata17 2014 P Asian mCRC SPR FOLFIRI 150mg/m2, biweekly M 34 62 0-2 7 
Zhao55 2014 P Asian SCLC Direct 
sequencing 
IRI+CDDP 60mg/m2 (d1,8,15), every 3 weeks S 34 49 0-2 8 
Song56 2014 P Asian Advanced OC NR IRI+PLA 60mg/m2 (d1,8), every 3 weeks S 89 48 NR 8 
Zhang57 2014 P Asian mCRC Sequencing FOLFIRI, XELIRI, 
IRIR 
180mg/m2, biweekly; 200mg/m2, 
every 3weeks 
S 102 55 NR 8 
Xu53 2014 P Asian GC Sequencing NR NR S 67 62.7 0-2 8 
Zhou58 2014 P Asian mCRC SPR IRI+5-FU/TMZ/CAP 180mg/m2 S 82 59 NR 8 
Zhou52 2013 P Asian gastrointestinal 
cancer 
Direct 
Sequencing 
FOLFIRI 180mg/m2, biweekly S 94 58.5 0-1 8 
Hirasawa50 2013 R Asian cervical or 
ovarian cancer 
Invader assay IRI+CDDP, IRI alone 60 or 100mg/m2 (d1, 8, 15), every 4 
weeks 
S 53 48 NR 7 
Gao48 2013 R Asian mCRC Sanger 
Sequencing 
FOLFIRI, IRI alone or 
IRI+CET/CAP 
180mg/m2 S 276 55 NR 7 
Gao49 2013 R Asian advanced GC Sanger 
Sequencing 
IRI+CDDP, FOLFIRI, 
IRI alone, IRI+CET 
180mg/m2 S 42 53 NR 7 
Gao49 2013 R Asian advanced 
esophageal 
cancer 
Sanger 
Sequencing 
IRI+CDDP, FOLFIRI, 
IRI alone, IRI+CET 
130mg/m2; 180mg/m2 S 91 54 NR 7 
Qin51 2013 R Asian advanced 
gastrointestinal 
carcinoma 
Sequencing IRI, IRI+CDDP, 
IRI+5-FU 
NR S 183 NR NR 7 
Wang45 2012 NR Asian mCRC Direct 
Sequencing 
FOLFIRI, IRI+LEU 180mg/m2, biweekly; 125mg/m2 
(d1, 8, 15, 22), every 6 weeks 
S 130 52 0-2 7 
Zhang46 2012 P Asian mCRC Direct 
Sequencing 
FOLFIRI, IRI+LEU 180mg/m2, biweekly; 125mg/m2 
(d1, 8, 15, 22), every 6 weeks 
S 56 55.5 NR 8 
Lamas34 2012 R Caucasian mCRC Fluorescent 
DNA length 
fragment 
analysis 
FOLFIRI, 
FOLFIRI-CET, 
FOLFIRI-BEV, 
IRI+CET 
180mg/m2, biweekly S 101 67 0-2 7 
Wang47 2012 P Asian mCRC Sequencing IFL, FOLFIRI 125mg/m2, 
weekly;180mg/m2,biweekly 
S 180 54 0-2 7 
Shulman33 2011 R Caucasian mCRC SPR FOLFIRI, IFL, 
TEGAFIRI, XELIRI 
U M 214 63.1 NR 8 
Okuyama43 2011 P Asian mCRC SPR FOLFIRI 150mg/m2 S 39 64 0-2 7 
Nakamura42 2011 P Asian mNSCLC Polyacrylamide 
gel 
electrophoresis 
IRI+PAC, IRI+GEM 50mg/m2 (d1, 8 and 15), every 4 
weeks; 100mg/m2 (d1 and 8), every 
3 weeks 
S 77 NR 0-1 8 
Park44 2011 P Asian mGC Sequencing S-1+IRI+OXA 150mg/m2, every 3 weeks S 44 54 0-2 7 
Mcleod32 2010 P Caucasian mCRC PYRS IRI+FU+LEU, 
IRI+OXA 
100-125mg/m2 (d1, 8, 15 and 22), 
every 6 weeks; 200mg/m2, every 3 
weeks 
M 212 61 0-2 8 
Ji41 2010 R Asian mCRC Sequencing FOLFIRI 180mg/m2, biweekly S 64 NR 0-2 7 
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Balibrea31 2010 P Caucasian mCRC Sequencing IRI+ 5-FU, 
IRI+5FU/LV 
80mg/m2, weekly; 180mg/m2, 
biweekly 
M 149 NR 0-2 8 
Han39 2009 P Asian mNSCLC SBE IRI+CDDP 65 or 80mg/m2 (d1 and 8), every 3 
weeks 
S 107 58 0-2 7 
Onoue40 2009 P Asian Mixed tumors Direct 
Sequencing 
IRI alone; IRI+plat; 
IRI+ other anticancer 
agents, FOLFIRI 
60-100mg/m2 S 133 NR 0-1 7 
Ferraldeschi18 2009 P Mixed mCRC SPR IRI, FOLFIRI, 
IRI+VEGF inhibitor 
350mg/m2, every 3 weeks; 
180mg/m2, biweekly 
S 92 62.9 NR 8 
Rouits29 2008 R Caucasian mCRC PYRS FOLFIRI 180mg/m2, biweekly S 44 60 0-2 8 
Parodi28 2008 P Caucasian mCRC SPR FOLFIRI, mIFL, 
CapeIRI 
125 or 180mg/m2, biweekly; 
250mg/m2, every 3 weeks 
M 110 NR 0-2 8 
Liu16 2008 R Asian mCRC SPR FOLFIRI 180mg/m2, biweekly S 128 NR 0-2 8 
Kweekel15 2008 R Caucasian mCRC PYRS IRI+CAP+OAX 250 or 350mg/m2 (d1), every 3 
weeks 
M 218 NR 0-2 8 
Wang38 2007 P Asian mCRC SPR FOLFIRI 180mg/m2, biweekly M 70 NR 0-3 8 
Ruzzo30 2007 P Caucasian mCRC SPR FOLFIRI 180mg/m2, biweekly M 146 61 NR 7 
Jada37 2007 NR Asian Mixed tumors SPR IRI 375 mg/m2, every 3 weeks S 45 55 0-2 7 
Cote14 2007 P Caucasian stage III colon 
cancer 
SPR LV5FU2+IRI 180 mg/m2 (d1), every 2 weeks M 89 NR NR 8 
Toffoli11 2006 P Caucasian mCRC PYRS mFOLFIRI or 
FOLFIRI 
180mg/m2 (d1), every 2 weeks M 250 60.6 0-2 8 
Massacesi12 2005 P Caucasian mCRC Sequencing IRI+RAL 80 weekly (d1, 8, 15 and 22), every 5 
weeks 
M 56 64 0-2 7 
Jong13 2006 P Caucasian Mixed tumors SPR IR+NEO 350mg/m2, every 3 weeks M 52 58 0-2 8 
Han36 2006 P Asian mNSCLC Direct 
Sequencing 
IRI+CDDP 80mg/m2 (d1 and 8), every 3 weeks S 81 NR 0-2 8 
Rouits27 2004 R Caucasian mCRC PYRS IRIFUFOL, FOLFIRI 85mg/m2, weekly; 180mg/m2, 
biweekly 
S 73 62 0-2 8 
Marcuello26 2004 P Caucasian mCRC SPR IRI alone, IRI+TOM, 
IRI+5-FU, 
IRI+5-FU+leuc 
80mg/m2, weekly; 180mg/m2, 
biweekly;3 50mg/m2, every 3 weeks 
S 95 68 0-2 8 
Innocenti67 2004 P Mixed Mixed tumors SBE IRI 350mg/m2, every 3 weeks S 59 60 NR 7 
Font66 2003 NR NR mNSCLC Sequencing IRI+DOC 70mg/m2 (d1, 8 and 15), every 4 
weeks 
S 47 55 0-2 7 
Iyer25 2002 P Caucasian Mixed tumors SPR IRI 300mg/m2, every 3 weeks S 20 NR NR 8 
R, analysis was planned retrospectively; P, analysis was planned prospectively; NR, Not reported; mCRC, metastatic colorectal cancer; GC, gastric cancer; SCLC, small-cell lung cancer; 
NSCLC, non-small-cell lung cancer; SPR, Sizing of PCR products (analysis of fragment size); PYRS, Pyrosequencing; SBE, Single base prime extension assay; IRI, irinotecan; CDDP, 
cisplatin; BEV, bevacizumab; OXA, oxaliplatin; CET, cetuximab; PLA, platinum; IFL, FU+IRI; CAP, capecitabine; CBP, carboplatin; LOB, lobaplatin; RAL, raltitrexed; 5-FU, 5-fluorouracil; 
LV, leucovorin; GCB, gemicitabine; TOM, toumdex; DOC, docetaxel; PAC, paclitaxel; IFL, IRI+5-FU/LV; FOLFIRI, FOL stands for folinic acid, F for fluorouracil, IRIR for irinotecan+5-FU; 
S, single center; M, multicenter; ECOG, Estern Cooperative Oncology Group; NOS: Newcastle-Ottawa Scale. 
 
 
 
Figure 2. Forest plot of diarrhea risk related to UGT1A1*28 polymorphism under the homozygous model. 
 Journal of Cancer 2017, Vol. 8 
 
http://www.jcancer.org 
696 
Table 2. Meta-analysis Results for diarrhea. 
Compared genotype Group No. of studies No. of participants OR 
(95%CI) 
P Test for heterogeneity 
P I2 
TA6/7 vs. TA6/6 All 28 3435 1.56 
(1.25-1.96) 
<0.001 0.175 19.9% 
mCRC 16 2563 1.60 
(1.11-2.31) 
0.011 0.034 43.3% 
SCLC 3 131 2.40 
(0.74-7.74) 
0.144 0.208 36.3% 
mNSCLC 3 235 0.92 
(0.34-2.54) 
0.879 0.883 0.0% 
Asian 18 2270 1.85 
(1.37-2.50) 
<0.001 0.334 10.1% 
Caucasian 9 1118 1.28 
(0.91-1.80) 
0.117 0.136 35.3% 
Retrospective 13 2123 1.70 
(1.09-2.66) 
0.020 0.032 46.8% 
Prospective 12 1090 1.69 
(1.13-2.52) 
0.010 0.495 0.0% 
TA7/7 vs. TA6/6 All 17 2610 3.97 
(1.88-8.38) 
<0.001 0.007 51.7% 
mCRC 14 1172 3.53 
(1.54-8.09) 
0.003 0.004 57.5% 
Asian 10 1805 8.98 
(5.21-15.47) 
<0.001 0.152 32.0% 
Caucasian 7 805 1.09 
(0.56-2.13) 
0.807 0.259 22.3% 
Retrospective 9 1737 4.84 
(1.32-17.69) 
0.017 <0.001 71.7% 
Prospective 7 743 2.86 
(1.30-6.30) 
0.009 0.555 0.0% 
TA6/7+7/7 vs. TA6/6 All 44 4868 2.18 
(1.68-2.83) 
<0.001 0.003 40.8% 
SCLC 3 131 3.95 
(1.42-11.01) 
0.009 0.115 53.8% 
mNSCLC 4 321 1.24 
(0.58-2.65) 
0.582 0.560 0.0% 
Advanced OC 2 178 7.09 
(2.91-17.26) 
<0.001 1.00 0.0% 
mCRC 25 3477 1.96 
(1.42-2.70) 
<0.001 0.005 47.3% 
Asian 32 3607 2.74 
(2.21-3.40) 
<0.001 0.132 22.2% 
Caucasian 11 1214 1.39 
(0.84-2.32) 
0.202 0.038 47.9% 
Retrospective 16 2359 2.17 
(1.36-3.49) 
0.001 0.001 62.0% 
Prospective 24 2198 2.12 
(1.62-2.79) 
<0.001 0.263 14.3% 
TA7/7 vs. TA6/7+TA6/6 All 24 3175 3.64 
(2.01-6.58) 
<0.001 <0.001 57.6% 
 SCLC 2 64 19.90 
(2.57-154.1) 
0.004 0.832 0.0% 
 mCRC 17 2656 3.16 
(1.61-6.19) 
0.001 <0.001 64.1% 
 Asian 13 1917 8.64 
(4.14-18.04) 
<0.001 0.092 36.3% 
 Caucasian 10 1211 1.62 
(1.03-2.53) 
0.035 0.188 27.8% 
 Retrospective 11 2003 2.06 
(1.23-3.44) 
0.006 0.168 32.5% 
 Prospective 11 995 2.92 
(1.64-5.21) 
<0.001 0.219 26.2% 
mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer. 
 
Meta-Analysis of UGT1A1*28 Polymorphism 
and Response 
Eighteen studies with 2024 patients were 
assessed to determine the association of the 
UGT1A1*28 polymorphism with tumor response to 
irinotecan-based chemotherapy (Table 4 and Figure 
4). A partial or complete remission was grouped as a 
response, while stable tumor or progression was 
considered no response. A response occurred in 
patients with at least one mutation allele but not in 
patients with the wide genotype (TA6/7+TA7/7 vs. 
TA6/6: OR = 1.20, 95%CI = 1.07–1.34, P = 0.016). The 
association was significant in Caucasians (OR = 1.23, 
95%CI = 1.06–1.42, P = 0.006), retrospective study 
designs (OR = 1.54, 95%CI = 1.06–2.23, P = 0.022), and 
mCRC patients (OR = 1.24, 95%CI = 1.05–1.48, P = 
0.014). 
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Heterogeneity Analysis  
There was high heterogeneity among studies 
evaluating severe diarrhea under the homozygous 
and recessive comparisons (TA7/7 vs. TA6/6: P = 
0.007, I2= 51.7%; TA7/7 vs. TA6/6+TA6/7: P<0.001, 
I2= 57.6%). We performed meta-regression to explore 
the sources of heterogeneity. The data indicated that 
ethnicity and year of publication accounted for 76% 
and 26% of heterogeneity under the homozygous 
model and 54% and 41% under the recessive model, 
respectively (data not shown). There was high 
heterogeneity among studies of neutropenia under 
recessive comparison (P<0.001, I2= 60.7%). The 
meta-regression results only revealed that the number 
of patients represented 25% of the heterogeneity and 
no other factors were found (data not shown). 
 
Table 3. Meta-analysis Results for neutropenia. 
Compared 
genotype 
Group No. of studies No. of participants OR (95%CI) P Test for heterogeneity 
P I2 
TA6/7 vs. TA6/6 All 32 3948 1.71 (1.41-2.08) < 0.001 0.104 24.8% 
mCRC 19 2801 1.76 (1.40-2.23) <0.001 0.434 1.8% 
mNSCLC 2 188 1.35 (0.55-3.34) 0.518 0.920 0.0% 
Asian 21 2547 1.56 (1.07-2.27) 0.020 0.011 46.0% 
Caucasian 10 1342 1.86 (1.34-2.60) <0.001 0.991 0.0% 
Retrospective 14 1468 1.90 (1.43-2.53) <0.001 0.201 23.3% 
Prospective 15 1448 1.53 (1.15-2.05) 0.004 0.882 0.0% 
TA7/7 vs. TA6/6 All 27 3575 5.34 (3.05-9.33) <0.001 0.003 48.7% 
mCRC 19 2801 5.07 (2.56-10.02) <0.001 0.001 59.3% 
Asian 15 2154 4.77 (1.71-13.22) 0.003 0.001 62.6% 
Caucasian 11 1362 5.39 (3.43-8.47) <0.001 0.342 10.7% 
Retrospective 12 1914 5.61 (3.58-8.82) <0.001 <0.001 69.3% 
Prospective 14 1531 5.81 (3.57-9.47) <0.001 0.291 14.8% 
TA6/7+7/7 vs. 
TA6/6 
All 49 5232 2.15 (1.71-2.70) <0.001 0.003 39.5% 
mCRC 26 3473 2.47 (1.86-3.27) <0.001 0.013 42.1% 
Advanced esophageal cancer 2 133 1.20 (0.48-3.05) 0.697 0.691 0.0% 
Advanced GC 4 193 1.40 (0.64-3.06) 0.402 0.759 0.0% 
mNSCLC 4 351 1.79 (0.97-3.33) 0.064 0.432 0.0% 
Asian 35 3715 2.11 (1.54-2.89) <0.001 <0.001 53.9% 
Caucasian 13 1458 2.29 (1.69-3.08) <0.001 0.992 0.0% 
Retrospective 18 2318 2.52 (1.64-3.88) <0.001 <0.001 59.3% 
Prospective 29 2739 1.90 (1.53-2.35) <0.001 0.530 0.0% 
TA7/7 vs. 
TA6/6+6/7 
All 28 3668 4.12 (2.36-7.20) <0.001 <0.001 60.7% 
mCRC 20 2894 3.70 (1.88-7.30) <0.001 <0.001 69.4% 
Asian 15 2154 4.16 (1.44-11.99) 0.008 <0.001 68.9% 
Caucasian 12 1455 3.39 (1.92-5.98) <0.001 0.057 42.7% 
Retrospective 12 1914 3.59 (1.05-12.28) 0.042 <0.001 76.4% 
Prospective 15 1624 4.10 (2.36-7.12) <0.001 0.088 35.1% 
mCRC, metastatic colorectal cancer; GC, gastric cancer; mNSCLC, metastatic non-small-cell lung cancer. 
 
 
Table 4. Meta-analysis Results for response. 
Group No. of studies No. of participants OR (95%CI) P Test for heterogeneity 
P I2 
All 18 2024 1.20 (1.07-1.34) 0.016 0.082 33.6% 
mCRC 12 1691 1.24 (1.05-1.48) 0.014 0.060 42.2% 
SCLC 2 64 0.87 (0.57-1.33) 0.514 0.458 0.0% 
mNSCLC 3 202 1.08 (0.71-1.63) 0.726 0.127 51.5% 
Asian 12 2270 1.08 (0.82-1.42) 0.168 0.019 51.7% 
Caucasian 5 1118 1.23 (1.06-1.42) 0.006 0.669 0.0% 
Retrospective 4 538 1.54 (1.06-2.23) 0.022 0.060 59.5% 
Prospective 12 1292 1.07 (0.93-1.22) 0.343 0.511 0.0% 
mCRC, metastatic colorectal cancer; mNSCLC, metastatic non-small-cell lung cancer 
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Figure 3. Forest plot of neutropenia risk related to UGT1A1*28 polymorphism under the homozygous model. 
 
 
 
Figure 4. Forest plot of response related to UGT1A1*28 polymorphism under the homozygous model. 
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Table 5. P values for Begg’s funnel plot and Egger’s test for 
diarrhea and neutropenia. 
 Begg Egger 
Diarrhea 
TA6/7 vs. TA6/6 0.635 0.244 
TA7/7 vs. TA6/6 0.365 0.166 
TA6/7+TA7/7 vs. TA6/6 0.927 0.282 
TA7/7 vs. TA6/6+TA6/7 0.215 0.697 
Neutropenia 
TA6/7 vs. TA6/6 0.284 0.088 
TA7/7 vs. TA6/6 0.755 0.999 
TA6/7+TA7/7 vs. TA6/6 0.044 0.027 
TA7/7 vs. TA6/6+TA6/7 0.782 0.617 
 
Publication Bias 
To detect publication bias in studies that 
evaluated diarrhea and neutropenia, we performed 
the Begg and Egger tests (Table 5). As shown in Table 
5, publication bias was found only among the studies 
of neutropenia under the dominant model (P = 0.027). 
Next, a trim and fill method was applied and the 
results (OR = 1.80, 95%CI = 1.37–2.36, P<0.001) 
showed no statistical difference compared from the 
results described above (OR = 2.15, 95%CI = 1.71–2.70, 
P<0.001). There was also no publication bias in studies 
evaluating response (P = 0.082). Thus, publication bias 
did not appear to affect our results. 
Sensitivity Analysis 
Statistical analysis was conducted as described 
previously [23]. As shown in Figure 5, 6, and 7, the 
results were not affected by omitting individual 
studies in this meta-analysis, indicating that our 
results are reliable.  
Trial Sequential analysis 
We used the dominant model as an example to 
perform the TSA, which included eighteen trials with 
2024 patients. The results showed the required 
information size was 1078, which meant our sample 
size was enough to get a robust conclusion about the 
UGT1A1*28 polymorphism and chemotherapy 
response (Figure 8). The required sample sizes for 
determining the associations between UGT1A1 and 
diarrhea and neutropenia under the dominant model 
were 763 and 1162, respectively (data were not 
shown). 
 
 
Figure 5. Sensitivity analysis of the studies about diarrhea under the homozygous model. 
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Figure 6. Sensitivity analysis of the studies about neutropenia under the homozygous model. 
 
 
Figure 7. Sensitivity analysis of the studies about response under the dominant model. 
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Figure 8. The required sample size to demonstrate the relationship between UGT11A1*28 polymorphism and chemotherapy response. The solid line represents the 
cumulative z-curve. The dashed curve represents the trial sequential monitoring boundary. 
 
Discussion 
A couple of meta-analyses have investigated the 
relationships between the UGT1A1*28 polymorphism 
and irinotecan-induced toxicity, severe diarrhea, and 
neutropenia. A study by Chen et al. in 2014 included 
six articles and found no statistically significant 
association between the UGT1A1*28 polymorphism 
and neutropenia in Asians (OR = 1.67, 95%CI = 
0.94–2.97) [65]. Liu et al.[66] conducted a 
meta-analysis of 16 articles and found that mCRC 
patients carrying the TA7/7 genotype had a higher 
risk of neutropenia and diarrhea in Caucasians. In 
contrast to previous studies, we evaluated 58 articles 
including 6087 cancer patients and performed 
stratified analyses based on ethnicity, study design, 
and cancer type. Statistical difference between the 
UGT1A1*28 polymorphism and diarrhea was 
confirmed in Asian patients and mCRC patients 
under the five models. Individuals with at least 
mutation allele had a 1.71- and 5.34-fold greater risk 
of neutropenia than individuals carrying the wide 
genotype. Mutated genotypes of the UGT1A1*28 
polymorphism may lower the glucuronidation rates 
of SN-38 and lead to greater susceptibility to severe 
toxicities [25, 36]. 
Patients evaluated in this study, particularly 
mCRC patients with the TA6/7 and TA7/7 
genotypes, may have severe diarrhea and neutropenia 
after irinotecan-induced chemotherapy. However, the 
UGT1A1*28 TA6/6 and TA7/7 genotypes may show 
an increased treatment response according to our 
results. In contrast to our results, Xu et al.[67] 
observed different clinical responses in Ugyur 
patients with different UGT1A1*28 polymorphism 
genotypes, but not in the Han population. Although 
the reduction of irinotecan was greater in patients 
with the TA7/7 or TA6/7 genotypes than the TA6/6 
genotype, no difference in overall or progression-free 
survival between the two group patients were found 
by Dias et al.[68]. These results indicate that if the 
patients with mutant genotypes could tolerate the 
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toxicities, irinotecan-based chemotherapy is a good 
choice for treatment. Additional studies of the 
treatment response should be carried out. 
Previous meta-analyses included few than 20 
studies and only focused on toxicities or 
chemotherapy response. In comparison with these 
studies, we included more research (58 studies) and 
investigated the associations of UGT1A1*28 
polymorphism with toxicities and chemotherapy 
effect. We also got a novel conclusion that patients 
with a higher risk of chemotherapy toxicities have a 
tendency to better response to chemotherapy. 
However, there were some limitations to our study. 
First, the number of studies of SCLC, mNSCLC, 
advanced GC, solid tumors, and other cancers were 
limited, and thus, larger sample sizes for a single 
tumor are needed to validate our results. Second, high 
heterogeneity existed among studies related to severe 
neutropenia under the recessive comparison. 
Although the number of patients could explain 25% of 
the heterogeneity, other influencing factors were not 
identified. Third, the studies we including selected 
different irinotecan doses in the chemotherapies, 
which may lead to some bias. 
Conclusions 
In conclusion, we detected a significant 
relationship between the UGT1A1*28 polymorphism 
and irinotecan-induced toxicity and response to 
irinotecan-based chemotherapy. This polymorphism 
may be useful as a detective index for cancer patients 
receiving irinotecan-based chemotherapy. 
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